BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vahdat S, Oermann EK, Collins SP, Yu X, Abedalthagafi M, Debrito P, Suy S, Yousefi S, Gutierrez CJ, Chang T, Banovac F, Anderson ED, Esposito G, Collins BT. CyberKnife radiosurgery for inoperable stage IA non-small cell lung cancer: 18F-fluorodeoxyglucose positron emission tomography/computed tomography serial tumor response assessment. J Hematol Oncol 2010;3:6. [PMID: 20132557 DOI: 10.1186/1756-8722-3-6] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Snider JW, Oermann EK, Chen V, Rabin J, Suy S, Yu X, Vahdat S, Collins SP, Banovac F, Anderson E, Collins BT. CyberKnife with Tumor Tracking: An Effective Treatment for High-Risk Surgical Patients with Single Peripheral Lung Metastases. Front Oncol 2012;2:63. [PMID: 22754870 DOI: 10.3389/fonc.2012.00063] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
2 Hu M, Xie P, Lee NY, Li M, Ho F, Lian M, Zhao S, Yang G, Fu Z, Zheng J, Ma L, Yu J. Hypoxia with 18F-fluoroerythronitroimidazole integrated positron emission tomography and computed tomography (18F-FETNIM PET/CT) in locoregionally advanced head and neck cancer: Hypoxia changes during chemoradiotherapy and impact on clinical outcome. Medicine (Baltimore) 2019;98:e17067. [PMID: 31577699 DOI: 10.1097/MD.0000000000017067] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 2.7] [Reference Citation Analysis]
3 Pyka T, Bundschuh RA, Andratschke N, Mayer B, Specht HM, Papp L, Zsótér N, Essler M. Textural features in pre-treatment [F18]-FDG-PET/CT are correlated with risk of local recurrence and disease-specific survival in early stage NSCLC patients receiving primary stereotactic radiation therapy. Radiat Oncol 2015;10:100. [PMID: 25900186 DOI: 10.1186/s13014-015-0407-7] [Cited by in Crossref: 70] [Cited by in F6Publishing: 72] [Article Influence: 10.0] [Reference Citation Analysis]
4 Tyran M, Charrier N, Darreon J, Madroszyk A, Tallet A, Salem N. Early PET-CT After Stereotactic Radiotherapy for Stage 1 Non-small Cell Lung Carcinoma Is Predictive of Local Control. In Vivo 2018;32:121-4. [PMID: 29275308 DOI: 10.21873/invivo.11213] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
5 Barillot I, Munier O, Hatime M, Mornex F. Stratégies d’évaluation de la réponse après irradiation stéréotaxique des cancers bronchiques primitifs et des métastases pulmonaires. Cancer/Radiothérapie 2014;18:308-12. [DOI: 10.1016/j.canrad.2013.12.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Agarwal R, Saluja P, Pham A, Ledbetter K, Bains S, Varghese S, Clements J, Kim YH. The effect of CyberKnife therapy on pulmonary function tests used for treating non-small cell lung cancer: a retrospective, observational cohort pilot study. Cancer Manag Res 2012;4:347-50. [PMID: 23091397 DOI: 10.2147/CMAR.S34194] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Gibbs IC, Loo BW Jr. CyberKnife stereotactic ablative radiotherapy for lung tumors. Technol Cancer Res Treat 2010;9:589-96. [PMID: 21070081 DOI: 10.1177/153303461000900607] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
8 Lee K, Le T, Hau E, Hanna GG, Gee H, Vinod S, Dammak S, Palma D, Ong A, Yeghiaian-Alvandi R, Buck J, Lim R. A systematic review into the radiological features predicting local recurrence after stereotactic ablative body radiotherapy (SABR) in patients with non-small cell lung cancer (NSCLC): Local recurrence features of NSCLC post-SABR. Int J Radiat Oncol Biol Phys 2021:S0360-3016(21)03235-1. [PMID: 34879247 DOI: 10.1016/j.ijrobp.2021.11.027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Bretschneider T, Ricke J, Gebauer B, Streitparth F. Image-guided high-dose-rate brachytherapy of malignancies in various inner organs - technique, indications, and perspectives. J Contemp Brachytherapy 2016;8:251-61. [PMID: 27504135 DOI: 10.5114/jcb.2016.61068] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
10 IJsseldijk MA, Shoni M, Siegert C, Wiering B, van Engelenburg KCA, Lebenthal A, Ten Broek RPG. Survival After Stereotactic Body Radiation Therapy for Clinically Diagnosed or Biopsy-Proven Early-Stage NSCLC: A Systematic Review and Meta-Analysis. J Thorac Oncol 2019;14:583-95. [PMID: 30721798 DOI: 10.1016/j.jtho.2018.12.035] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
11 Gill BS, Rivandi AH, Sandhu SP, Jensen LG, Nobiensky PD, Hoh CK, Sandhu AP. The role of positron emission tomography following radiosurgical treatment of malignant lung lesions. Nuclear Medicine Communications 2012;33:607-12. [DOI: 10.1097/mnm.0b013e3283512b08] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
12 Tan D, Gill S, Loh N. Timing of fluorodeoxyglucose positron emission tomography maximum standardized uptake value for diagnosis of local recurrence of non-small cell lung cancer after stereotactic body radiation therapy. Cancer Med 2020;9:7469-76. [PMID: 32846054 DOI: 10.1002/cam4.3302] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Nuyttens JJ, van de Pol M. The CyberKnife radiosurgery system for lung cancer. Expert Review of Medical Devices 2014;9:465-75. [DOI: 10.1586/erd.12.35] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 5.8] [Reference Citation Analysis]
14 Wu VW, Tam KW, Tong SM. Evaluation of the influence of tumor location and size on the difference of dose calculation between Ray Tracing algorithm and Fast Monte Carlo algorithm in stereotactic body radiotherapy of non-small cell lung cancer using CyberKnife. J Appl Clin Med Phys 2013;14:68-78. [PMID: 24036860 DOI: 10.1120/jacmp.v14i5.4280] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
15 Factor OB, Vu CC, Schneider JG, Witten MR, Schubach SL, Gittleman AE, Catell DT, Haas JA. Stereotactic body radiation therapy for stage I non-small cell lung cancer: a small academic hospital experience. Front Oncol 2014;4:287. [PMID: 25368843 DOI: 10.3389/fonc.2014.00287] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
16 Essler M, Wantke J, Mayer B, Scheidhauer K, Bundschuh R, Haller B, Astner S, Molls M, Andratschke N. Positron-emission tomography CT to identify local recurrence in stage I lung cancer patients 1 year after stereotactic body radiation therapy. Strahlenther Onkol 2013;189:495-501. [DOI: 10.1007/s00066-013-0310-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
17 Aghdam N, Lischalk JW, Marin MP, Hall C, O'Connor T, Campbell L, Suy S, Collins SP, Margolis M, Krochmal R, Anderson E, Collins BT. Lobar Gross Endobronchial Disease Predicts for Overall Survival and Grade 5 Pulmonary Toxicity in Medically Inoperable Early Stage Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy. Front Oncol 2021;11:728519. [PMID: 34912703 DOI: 10.3389/fonc.2021.728519] [Reference Citation Analysis]
18 Streitparth T, Schumacher D, Damm R, Friebe B, Mohnike K, Kosiek O, Pech M, Ricke J, Streitparth F. Percutaneous radiofrequency ablation in the treatment of pulmonary malignancies: efficacy, safety and predictive factors. Oncotarget 2018;9:11722-33. [PMID: 29545932 DOI: 10.18632/oncotarget.24270] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
19 Bibault JE, Oudoux A, Durand-Labrunie J, Mirabel X, Lartigau É, Kolesnikov-Gauthier H. [Positron emission tomography and stereotactic body radiation therapy for lung cancer: From treatment planning to response evaluation]. Cancer Radiother 2015;19:790-4; quiz 795-9. [PMID: 26476702 DOI: 10.1016/j.canrad.2015.05.027] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
20 Janvary ZL, Jansen N, Baart V, Devillers M, Dechambre D, Lenaerts E, Seidel L, Barthelemy N, Berkovic P, Gulyban A, Lakosi F, Horvath Z, Coucke PA. Clinical Outcomes of 130 Patients with Primary and Secondary Lung Tumors treated with Cyberknife Robotic Stereotactic Body Radiotherapy. Radiol Oncol 2017;51:178-86. [PMID: 28740453 DOI: 10.1515/raon-2017-0015] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
21 Jin L, Price RA, Wang L, Meyer J, Fan JJ, Ma CM. Dosimetric and delivery efficiency investigation for treating hepatic lesions with a MLC-equipped robotic radiosurgery-radiotherapy combined system. Med Phys 2016;43:727-33. [PMID: 26843236 DOI: 10.1118/1.4939259] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
22 Moran DE, Parikh M, Sheiman RG, Brook OR, Sun MRM, Mahadevan A, Siewert B. Comparison of technical success and safety of transbronchial versus percutaneous CT-guided fiducial placement for SBRT of lung tumors. J Med Imaging Radiat Sci 2021:S1939-8654(21)00131-4. [PMID: 34229986 DOI: 10.1016/j.jmir.2021.06.004] [Reference Citation Analysis]
23 Pierson C, Grinchak T, Sokolovic C, Holland B, Parent T, Bowling M, Arastu H, Walker P, Ju A. Response criteria in solid tumors (PERCIST/RECIST) and SUVmax in early-stage non-small cell lung cancer patients treated with stereotactic body radiotherapy. Radiat Oncol 2018;13:34. [PMID: 29486779 DOI: 10.1186/s13014-018-0980-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
24 Boily G, Filion É, Rakovich G, Kopek N, Tremblay L, Samson B, Goulet S, Roy I. Stereotactic Ablative Radiation Therapy for the Treatment of Early-stage Non–Small-Cell Lung Cancer: CEPO Review and Recommendations. Journal of Thoracic Oncology 2015;10:872-82. [DOI: 10.1097/jto.0000000000000524] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
25 Adebahr S, Collette S, Shash E, Lambrecht M, Le Pechoux C, Faivre-Finn C, De Ruysscher D, Peulen H, Belderbos J, Dziadziuszko R, Fink C, Guckenberger M, Hurkmans C, Nestle U. LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective. Br J Radiol 2015;88:20150036. [PMID: 25873481 DOI: 10.1259/bjr.20150036] [Cited by in Crossref: 52] [Cited by in F6Publishing: 54] [Article Influence: 7.4] [Reference Citation Analysis]
26 Huang K, Dahele M, Senan S, Guckenberger M, Rodrigues GB, Ward A, Boldt RG, Palma DA. Radiographic changes after lung stereotactic ablative radiotherapy (SABR)--can we distinguish recurrence from fibrosis? A systematic review of the literature. Radiother Oncol. 2012;102:335-342. [PMID: 22305958 DOI: 10.1016/j.radonc.2011.12.018] [Cited by in Crossref: 139] [Cited by in F6Publishing: 121] [Article Influence: 13.9] [Reference Citation Analysis]
27 Ijsseldijk MA, Shoni M, Siegert C, Wiering B, van Engelenburg AKC, Tsai TC, Ten Broek RPG, Lebenthal A. Oncologic Outcomes of Surgery Versus SBRT for Non-Small-Cell Lung Carcinoma: A Systematic Review and Meta-analysis. Clin Lung Cancer 2021;22:e235-92. [PMID: 32912754 DOI: 10.1016/j.cllc.2020.04.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Chi A, Wen S, Liao Z, Fowler J, Xu J, Nguyen NP, Welsh JS, Komaki R. What would be the most appropriate α/β ratio in the setting of stereotactic body radiation therapy for early stage non-small cell lung cancer. Biomed Res Int 2013;2013:391021. [PMID: 24350266 DOI: 10.1155/2013/391021] [Cited by in Crossref: 11] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
29 Sawada S, Suehisa H, Ueno T, Sugimoto R, Yamashita M. Monitoring and management of lung cancer patients following curative-intent treatment: clinical utility of 2-deoxy-2-[fluorine-18]fluoro-d-glucose positron emission tomography/computed tomography. Lung Cancer (Auckl) 2016;7:45-51. [PMID: 28210160 DOI: 10.2147/LCTT.S83644] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
30 Chassagnon G, Martini K, Giraud P, Revel MP. Radiological assessment after stereotactic body radiation of lung tumours. Cancer Radiother 2020;24:379-87. [PMID: 32534799 DOI: 10.1016/j.canrad.2020.04.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Mohammed N, Grills IS, Wong CY, Galerani AP, Chao K, Welsh R, Chmielewski G, Yan D, Kestin LL. Radiographic and metabolic response rates following image-guided stereotactic radiotherapy for lung tumors. Radiother Oncol. 2011;99:18-22. [PMID: 21458087 DOI: 10.1016/j.radonc.2011.03.003] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
32 Karam SD, Horne ZD, Hong RL, Baig N, Gagnon GJ, McRae D, Duhamel D, Nasr NM. Robotic stereotactic body radiation therapy for elderly medically inoperable early-stage non-small cell lung cancer. Lung Cancer (Auckl) 2013;4:35-42. [PMID: 28210133 DOI: 10.2147/LCTT.S48121] [Reference Citation Analysis]
33 Sarwate D, Sarkar S, Krimsky WS, Burgan CM, Patel K, Evans R, Harley DP. Optimization of mediastinal staging in potential candidates for stereotactic radiosurgery of the chest. The Journal of Thoracic and Cardiovascular Surgery 2012;144:81-6. [DOI: 10.1016/j.jtcvs.2012.03.004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
34 Pepin EW, Wu H, Zhang Y, Lord B. Correlation and prediction uncertainties in the cyberknife synchrony respiratory tracking system. Med Phys 2011;38:4036-44. [PMID: 21859002 DOI: 10.1118/1.3596527] [Cited by in Crossref: 73] [Cited by in F6Publishing: 59] [Article Influence: 6.6] [Reference Citation Analysis]
35 Nuyttens JJ, Moiseenko V, Mclaughlin M, Jain S, Herbert S, Grimm J. Esophageal Dose Tolerance in Patients Treated With Stereotactic Body Radiation Therapy. Seminars in Radiation Oncology 2016;26:120-8. [DOI: 10.1016/j.semradonc.2015.11.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
36 Soldà F, Lodge M, Ashley S, Whitington A, Goldstraw P, Brada M. Stereotactic radiotherapy (SABR) for the treatment of primary non-small cell lung cancer; systematic review and comparison with a surgical cohort. Radiother Oncol. 2013;109:1-7. [PMID: 24128806 DOI: 10.1016/j.radonc.2013.09.006] [Cited by in Crossref: 118] [Cited by in F6Publishing: 115] [Article Influence: 13.1] [Reference Citation Analysis]
37 Takeda A, Kunieda E, Fujii H, Yokosuka N, Aoki Y, Oooka Y, Oku Y, Ohashi T, Sanuki N, Mizuno T, Ozawa Y. Evaluation for local failure by 18F-FDG PET/CT in comparison with CT findings after stereotactic body radiotherapy (SBRT) for localized non-small-cell lung cancer. Lung Cancer 2013;79:248-53. [PMID: 23246123 DOI: 10.1016/j.lungcan.2012.11.008] [Cited by in Crossref: 42] [Cited by in F6Publishing: 33] [Article Influence: 4.2] [Reference Citation Analysis]
38 Chi A, Chen H, Wen S, Yan H, Liao Z. Comparison of particle beam therapy and stereotactic body radiotherapy for early stage non-small cell lung cancer: A systematic review and hypothesis-generating meta-analysis. Radiother Oncol 2017;123:346-54. [PMID: 28545956 DOI: 10.1016/j.radonc.2017.05.007] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 6.2] [Reference Citation Analysis]
39 Zhang J, Yang F, Li B, Li H, Liu J, Huang W, Wang D, Yi Y, Wang J. Which Is the Optimal Biologically Effective Dose of Stereotactic Body Radiotherapy for Stage I Non–Small-Cell Lung Cancer? A Meta-Analysis. International Journal of Radiation Oncology*Biology*Physics 2011;81:e305-16. [DOI: 10.1016/j.ijrobp.2011.04.034] [Cited by in Crossref: 106] [Cited by in F6Publishing: 105] [Article Influence: 9.6] [Reference Citation Analysis]
40 Hayes SA, Plodkowski AJ, Ginsberg MS. Imaging of Thoracic Cavity Tumors. Surgical Oncology Clinics of North America 2014;23:709-33. [DOI: 10.1016/j.soc.2014.06.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
41 Tong AN, Yan P, Yuan GH, Lv XY, Gong H, Zhao H, Wang YM. Advantages of CyberKnife for inoperable stage I peripheral non-small-cell lung cancer compared to three-dimensional conformal radiotherapy. Mol Clin Oncol 2015;3:442-8. [PMID: 25798283 DOI: 10.3892/mco.2014.475] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
42 Chen VJ, Oermann E, Vahdat S, Rabin J, Suy S, Yu X, Collins SP, Subramaniam D, Banovac F, Anderson E, Collins BT. CyberKnife with Tumor Tracking: An Effective Treatment for High-Risk Surgical Patients with Stage I Non-Small Cell Lung Cancer. Front Oncol 2012;2:9. [PMID: 22655258 DOI: 10.3389/fonc.2012.00009] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
43 Colt HG, Murgu SD, Korst RJ, Slatore CG, Unger M, Quadrelli S. Follow-up and Surveillance of the Patient With Lung Cancer After Curative-Intent Therapy. Chest 2013;143:e437S-54S. [DOI: 10.1378/chest.12-2365] [Cited by in Crossref: 118] [Cited by in F6Publishing: 104] [Article Influence: 13.1] [Reference Citation Analysis]
44 Mahasittiwat P, Yuan S, Xie C, Ritter T, Cao Y, Ten Haken RK, Kong FM. Metabolic Tumor Volume on PET Reduced More than Gross Tumor Volume on CT during Radiotherapy in Patients with Non-Small Cell Lung Cancer Treated with 3DCRT or SBRT. J Radiat Oncol 2013;2:191-202. [PMID: 23795245 DOI: 10.1007/s13566-013-0091-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]